Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bergamottin in prevention or treatment of osteoporosis and/or bone loss

A technology of bergamot and osteoporosis, which is applied in the field of biomedicine to achieve the effect of increasing bone density, increasing bone mass and restoring bone microstructure

Pending Publication Date: 2021-11-16
NORTHWESTERN POLYTECHNICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Bergamottin (BM) is a natural compound derived from a variety of citrus fruits, which has various biological activities such as anti-tumor, anti-inflammation, and anti-oxidation. Its application in the treatment of osteoporosis has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bergamottin in prevention or treatment of osteoporosis and/or bone loss
  • Application of bergamottin in prevention or treatment of osteoporosis and/or bone loss
  • Application of bergamottin in prevention or treatment of osteoporosis and/or bone loss

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1: Effect of bergamot on osteoblast differentiation

[0038] a. Culture of mouse preosteogenic cell line MC3T3-E1 cells

[0039] MC3T3-E1 cells were cultured with complete medium (α-MEM solution, supplemented with 10% fetal bovine serum, 10 mM L-glutamine, 100 μg / mL penicillin, 100 μg / mL streptomycin sulfate), and the cells were placed at 37°C for 5 %CO 2 cultured in an incubator.

[0040] b. Osteogenic differentiation induction of MC3T3-E1 cells

[0041] After MC3T3-E1 pre-osteoblasts were cultured until the cell fusion reached 100%, the cells in the control group were treated with osteogenic differentiation medium (α-MEM solution, 10% fetal bovine serum, 10mM L-glutamine, 100U / mL Penicillin, 100 μg / mL streptomycin sulfate, 0.005% vitamin C, 10mM β-sodium glycerophosphate) were used to induce osteogenic differentiation, and the cells in the experimental group were cultured with osteogenic differentiation medium (α-MEM solution) added with different concentra...

Embodiment 2

[0060] Example 2: Effect of bergamot on the expression of osteoblast-related proteins

[0061] MC3T3-E1 pre-osteoblasts were cultured for 48 hours after induction of osteogenic differentiation, and the cells were lysed by radioimmunoprecipitation (RIPA) lysis buffer (Shanghai Beyond Biotechnology Co., Ltd.) The protein concentration was determined by the BCA method. Protein expression was detected by immunoprecipitation (western-blot).

[0062] Figure 4 It is a schematic diagram of the results of detecting osteoblast-related proteins Wnt3a, LRP6, and β-catenin by western-blot detection method after treating MC3T3-E1 cells with different concentrations of bergamot in this example. Compared with the control group, the expressions of osteoblast-related proteins Wnt3a, LRP6, and β-catenin in MC3T3-E1 cells were significantly up-regulated in a dose-dependent manner after treatment with different concentrations of bergamot. The expressions of Wnt3a, LRP6, and β-catenin were posi...

Embodiment 3

[0063] Embodiment 3: Therapeutic effect of bergamot on osteoporosis mice

[0064] a. Establishment of postmenopausal osteoporosis model in mice and treatment with bergamot

[0065] Eight-week-old C57BL / 6 female mice were randomly divided into 4 groups, 6 mice / group: sham operation group (sham), ovariectomized group (OVX), ovariectomized bergamot low-dose treatment group (OVX +BM L, 15mg / kg), high-dose bergamotin treatment group after ovariectomy (OVX+BM H, 30mg / kg). After the mice were anesthetized with pentobarbital sodium, ovariectomy was performed (the adipose tissue of the same volume as the ovary was removed in the sham operation group). One week after recovery from surgery, high and low doses of bergamot were given to mice by gavage, once a day, for 8 weeks, and the therapeutic effect of bergamot on osteoporosis mice was detected. b. Micro-CT detection of mouse femur morphology

[0066] Mice were killed by neck dislocation, the femur was stripped out, the soft tissue ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of bergamottin or a pharmaceutically acceptable derivative thereof in preparation of reagents, medicines, health care products, functional foods and the like for treating, preventing and relieving osteoporosis and / or bone loss. According to the invention, the in-vitro experiments prove that the bergamottin can promote osteoblast differentiation, and can up-regulate the expression of osteoblast specific genes Alp, Runx2, Col-1 and Ocn and the expression of osteoblast related proteins Wnt3a, LRP6 and beta-catenin. In addition, in-vivo animal experiments prove that the bergamotin obviously increases the bone mineral density of a postmenopausal osteoporosis model animal, recovers the bone microstructure, increases the bone mass, can effectively treat osteoporosis and prevents bone loss caused by ovariectomy or insufficient estrogen. The compound has potential to be developed into reagents, medicines, health care products or functional foods for treating osteoporosis.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to an application of bergamot in preventing or treating osteoporosis and / or bone loss. Background technique [0002] Osteoporosis is a degenerative bone disease characterized by decreased bone mass and degeneration of bone microstructure, resulting in increased bone fragility and susceptibility to fracture. It is a systemic metabolic bone disease. With the improvement of average human life expectancy and the aggravation of population aging, osteoporosis has become a global public health problem, seriously affecting the health and quality of life of the elderly, especially postmenopausal women. It is estimated that more than 90 million people in the world suffer from osteoporosis, and patients often face pain, hunchback, height loss, decreased respiratory function, hip and other fractures, among which fractures are more common. The prevention and treatment of osteopo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P19/10A23L33/00
CPCA61K31/37A61P19/10A23L33/00A23V2002/00A23V2200/306
Inventor 骞爱荣田野王雪王味思梁学超
Owner NORTHWESTERN POLYTECHNICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com